Koumarianou, A. http://orcid.org/0000-0002-4159-2511
Makrantonakis, P.
Zagouri, F.
Papadimitriou, C.
Christopoulou, A.
Samantas, E.
Christodoulou, C.
Psyrri, A.
Bafaloukos, D.
Aravantinos, G.
Papakotoulas, P.
Baka, S.
Andreadis, C.
Alexopoulos, A.
Bompolaki, I.
Kampoli, Κ.
Liori, S.
Karvounis, K.
Ardavanis, A.
Funding for this research was provided by:
Genesis Pharma
Article History
Received: 26 March 2020
Accepted: 9 May 2020
First Online: 16 May 2020
Compliance with ethical standards
:
: AK: honoraria for consultation or advisory board, study investigator fees from Genesis pharma; PM: study investigator fees from Genesis pharma; FZ: honoraria for lectures, consultation, or advisory board participation from Novartis, Pfizer, Astra Zeneca, Daiichi Sankyo, Roche, Merck, Lilly, study investigator fees from Genesis pharma; CP, AC, AP, DB, GA, and AA: honoraria for advisory board, study investigator fees from Genesis pharma; ; ES and AA: honoraria for consultation or advisory board, study investigator fees from Genesis pharma; CC: honoraria for advisory board from Genesis pharma; PP, SB, CA, SL, and IB: study investigator fees from Genesis pharma; KK: has declared no conflict of interest and Genesis pharma Medical Department employe.